<DOC>
	<DOCNO>NCT02952742</DOCNO>
	<brief_summary>This randomize , placebo-controlled crossover study . Participants actively participate study 6 month , enrol study 1 year . During first phase study , participant randomize either placebo group treatment group 8 week follow 1 week baseline data collection ( treatment ) . Following first phase , no-treatment washout period least 3 week implement participant . After washout period , randomize group switch treatment placebo group , placebo treatment group additional 8 week period . Hot flash frequency severity document use daily hot flash diary calculate use Hot Flash Score questionnaire . The impact quality life document weekly Hot Flash Related Daily Interference Scale ( HFRDIS ) questionnaires .</brief_summary>
	<brief_title>Black Cohosh Host Flashes Due Androgen Deprivation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Able understand English wiling use train interpreter Diagnosis prostate cancer Receiving either Leuprolide Degarelix , prostate cancer treatment Currently experience minimum 3 selfreported hot flash within 24 hour period Eastern Cooperative Oncology Group ( ECOG ) performance status score &lt; 2 Life expectancy &gt; 3 month . No grade 3 high toxicity prior cancer therapy unless judge principal investigator clinically irrelevant study procedure At least four ( 4 ) week follow prior major surgery Serum testosterone concentration castrate level ( &lt; 30 ng/dL ) time recruitment Willing provide write informed consent participation study Concurrent severe illness effect ECOG performance status life expectancy determine principal investigator Hormone refractory patient . Patients take Enzalutamide Abiraterone . Active infection Psychiatric illness social situation would limit safety compliance study requirement Currently take pharmaceutical medication potential interaction black cohosh determine principal investigator Currently take supplement potential interaction black cohosh determine principal investigator Currently receive treatment hot flash plan initiate treatment hot flash study supplementation ALT , AST , Bilirubin &gt; 2 time normal laboratory value past 3 month Inability complete inform consent process adhere protocol treatment plan .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>